FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new carboxamide compounds of formula I-A' or I-A" , as well as to tautomers thereof and pharmaceutically acceptable salts thereof, wherein R1 means hydrogen, C1-C10-alkyl, C3-C7-cycloalkyl-C1-C4alkyl, aryl-C1-C6-alkyl or hetaryl-C1-C4-alkyl, wherein aryl and hetaryl in the two last mentioned radicals may be substituted or have 1 radical R1c; wherein R1a represents C1-C6-alkoxy, R1c is independently specified in halogen, CN, CF3, O-CF3, O-CHF2, C1-C6-alkyl, C1-C6-alkoxy, hetaryl, O-CH2-aryl, - (CH2)p-NRc6Rc7 with p = 0 or 1; wherein Rc6 represents C1-C6-alkyl or SO2-C1-C6-alkyl, and Rc7 represents C1-C6-alkyl, or the two radicals Rc6 and Rc7 together with an N atom form 5- or 6-member, optionally substituted C1-C4-alkyl nitrogen-containing heterocyclyl which can optionally have 1 heteroatom from the group O and N as ring members, R2 means C1-C10-alkyl, C3-C7-cycloalkyl, aryl, hetaryl, wherein aryl and hetaryl in the two last mentioned radicals may be unsubstituted or carry 1, 2 or 3 identical or different R2c radicals; wherein R2c have one of the values specified for R1c; R3a and R3b together with a carbon atom whereto attached, are C=O; X means hydrogen or a radical of formulas C(=O)-O-Rx1 or C(=O)-NRx2Rx3, wherein Rx1 means C1-C6-alkyl, Rx2 means H or C1-C6-alkyl, and Rx2 means H, one of the variables Y1, Y2, Y3 and Y4 forms a nitrogen atom, and the rest variables Y1, Y2, Y3 and Y4 mean CH, n is equal to 0 or 1, Ry is independently specified in halogen, CN, aryl, -NH-SO2-Ry4, -(CH2)p-NRy6Ry7 with p = 0; wherein Ry4 means C1-C6-alkyl, Ry6 has one of the values specified for Rc6, and Ry7 has one of the values specified for Rc7; m means 0 or 1 for formulas I-A', and Rw is specified in halogen, C1-C6-alkyl, C1-C6-alkoxy, wherein C1-C6-alkyl can have 1 substitute Rwa, aryl, -(CH2)p-NRw6Rw7 with p = 0 or 1, Rwa has one of the values specified for R1a, or represents NRa2SO2Ra4, Ra2 represents H, Ra4 represents C1-C6-alkyl, Rw6 has one of the values specified for Rc6, Rw7 has one of the values specified for Rc7, m is equal to 0, 1 or 2 for formula I-A", and Rw6* has one of the values specified for Rw, E has one of the values specified for: -CHRE 2-CHRE 3-, -CH2-O-, -O-CH2-, -S-CH2-, -CH2-S-, -CH2-SO2-, -SO2-CH2-, wherein Re 2, Re 3 represent hydrogen; wherein aryls defined above, represent mono- or bicyclic aromatic hydrocarbon radicals such as phenyl or naphthyl, and hetaryls defined above, represent 5 - or 6-member aromatic heterocyclic radicals containing 1 or 2 heteroatoms specified in nitrogen, oxygen and sulphur and can additionally contain a condensed benzene ring. Also, the invention refers to specific compounds, pharmaceutical compositions containing them and use thereof.
EFFECT: there are prepared new derivatives of carboxamide compounds effective in the treating the disorders caused by higher activity of calpain.
15 cl, 1 tbl, 195 ex
Title | Year | Author | Number |
---|---|---|---|
CARBOXAMIDE COMPOUNDS AND USE THEREOF AS CALPAIN INHIBITORS | 2010 |
|
RU2567392C2 |
CARBOXAMIDE COMPOUNDS AND USING THEM AS CALPAIN INHIBITORS | 2010 |
|
RU2540856C2 |
PYRAZOLOPYRIDINE DERIVATIVES AS NADPH-OXIDASE INHIBITORS | 2009 |
|
RU2538041C2 |
PYRAZOLOPYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | 2009 |
|
RU2532161C2 |
PYRAZOLO[3,4-b]PURIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION (VERSIONS), APPLICATION (VERSIONS), COMBINATION (VERSIONS) | 2003 |
|
RU2357967C2 |
PYRROLO- AND THIAZOLOPYRIDINE COMPOUNDS (VERSIONS) AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2461557C2 |
PYRAZOLE PYRIDINE DERIVATIVES AS NADPH-OXIDASE | 2009 |
|
RU2548022C2 |
CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
PHARMACEUTICAL COMPOSITION CONTAINING BENZODIAZEPINE DERIVATIVES AND RSV FUSION PROTEIN INHIBITOR | 2005 |
|
RU2388476C2 |
METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | 2012 |
|
RU2665021C2 |
Authors
Dates
2013-06-20—Published
2007-12-28—Filed